In vitro diagnostics will be the biggest growth sector in medtech sales, according to a new report from EvaluateMedTech. The data, released at this week’s AdvaMed 2015 conference in San Diego, paints a rosier picture of the medical device industry than many other reports of late – shining some optimism on the broader global market. Here are some top-line trends:
The world medtech sales forecast is projected to hit $477.5 billion by 2020. It’ll grow more slowly than the pharma sector – which is projected to have a CAGR of 4.9 percent. Medtech has a projected CAGR of 4.1 percent between 2014 and 2020. Similarly, the worldwide medtech R&D spend is expected to grow at least by 3.5 percent by 2020, reaching $29.5 billion.
Here’s how it’s projected to play out, in terms of device areas:
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Indeed, as precision medicine zooms ahead, it makes rational sense that the growth rate corresponds accordingly:
Johnson & Johnson leads the pack in terms of device sales, followed by Medtronic and Siemens:
The industry is dominated by a small number of larger players, as seen here:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
And as expected, pharmaceutical sales will dominate medtech in life science industry sales: